M embranous nephropathy (MN) is a common cause of nephrotic syndrome in adults and can be primary or secondary. Primary MN is most commonly associated with antiÀM-type phospholipase A2 receptor (PLA2R) antibodies and is usually IgG4 dominant, whereas secondary MN can be seen in the setting of malignancies, infections, autoimmune diseases, or as a side effect of certain medications or toxins, and is most commonly IgG1 dominant. 1, 2 The occurrence of crescents in MN is extremely rare, with a prevalence estimated between 0.39% 3 and 0.26%. 4 Crescents can be seen in both primary and secondary MN 3À5 or in association with a superimposed disease process, such as antiÀneutrophil cytoplasmic antibody (ANCA)Àassociated glomerulonephritis or antiÀglomerular basement membrane (GBM) disease. Previous series in the United States have either focused on cases of MN with crescents in the absence of ANCAs or anti-GBM antibodies, 3 or in association with ANCAs. 5 In light of the recently published series of MN with crescents from the United Kingdom, 4 and given the rarity of this entity, we analyzed its prevalence and its clinical and pathological characteristics in biopsy findings reviewed at our institution.
A total of 14,800 native and transplant renal biopsy specimens were received at the Ohio State University from 2010 to 2019. Of these, 15 cases (0.1%) showed MN with crescents (fibrous crescents only, 3; diffuse crescents [in >50% of glomeruli], 3; focal crescents [in <50% of glomeruli], 9). In addition, 3 cases had only segmental subepithelial deposits (segmental MN). Cases of lupus nephritis were excluded. PLA2R staining was performed retrospectively in 7 cases.
There were 8 female and 7 male patients. Two had anti-GBM antibodies (Figure 1a-d Table 1 and pathological features in Table 2 . One patient had prior ANCA-associated cutaneous vasculitis, and 1 patient had prior biopsy-proven infection-related glomerulonephritis; both had a history of cocaine use. Potential secondary causes of MN included solid organ malignancies (n ¼3), hepatitis C (n ¼ 2), and rheumatoid arthritis (n ¼ 1). Three patients had a monoclonal gammopathy of undetermined significance, and 5 patients had positive autoantibodies (4 antiÀnuclear antibodies, 2 anticardiolipin, and 2 anti-SSB). Eight patients had pulmonary symptoms, including hemoptysis in 3 and documented diffuse alveolar hemorrhage in 2. Twelve patients had hematuria, which was usually significant, and 14 had proteinuria (1 patient was anuric). Proteinuria was measured by spot urine protein-to-creatinine ratio or 24-hour collection and was >3 g in 7 of the 14 patients. Median creatinine at presentation was 2.9 mg/dl (1.07À18.6). Two patients had normal renal function on presentation (1 patient had a single fibrous and the other a single cellular crescent). The remaining 13 patients had estimated glomerular filtration rate of <60 ml/min per 1.73 m 2 . Eleven patients presented with severe kidney dysfunction (eGFR #30 ml/min per 1.73 m 2 ), 4 of whom required dialysis (2 with anti-GBM and 2 with MPO). Twelve patients received immunosuppression, 2 did not (1 had end-stage renal disease [ESRD]), and the other had a single fibrous crescent on biopsy); treatment data were not available for 1 patient. The most common drugs used were corticosteroids (n ¼ 11) and cyclophosphamide (n ¼ 10), followed by mycophenolate mofetil (MMF) (n ¼ 4), azathioprine (n ¼ 1), and rituximab (n ¼ 1). Plasmapheresis was performed in 3 patients: 2 with anti-GBM and 1 with myeloperoxidase (MPO) antibodies and hemoptysis. Follow-up data were available for 13 patients, with a median follow-up of 38 months (4À98 months). Of these 13 patients, 5 reached ESRD (3 MPO, 2 anti-GBM), of whom 3 received a kidney transplant. Of the patients who reached ESRD, 2 had >50% crescents on biopsy, and 1 patient had >90% interstitial fibrosis and tubular atrophy (IFTA); the other 2 patients had up to 25% crescents and 25% to 35% IFTA ( Table 2) . Five patients developed chronic kidney disease, 2 died (both had solid organ malignancies), and only 3 (20%) had eGFR >60 ml/min 1.73 m 2 (all of these patients had only focal crescents and mild IFTA on biopsy). Conversely, renal survival in MN without crescents is estimated to be between 70% and 90%. 6 Overall, our series findings are similar to those recently reported by Nikolopoulou et al., 4 with approximately 40% of patients reaching ESRD. We had a greater number of anti-PLA2RÀpositive cases (26% vs. 13%), whereas they had a greater number of anti-GBMÀpositive patients (33% vs. 13%). Interestingly, however, outcomes were similar, which may be due to the fact that the prognosis of anti-GBM disease tends to be better in cases with associated MN, 7 with close to 40% of patients recovering renal function 8 in contrast to only 15% in pure anti-GBM disease. S1 Potential explanations for that could be overall lower levels of anti-GBM antibodies in patients with concomitant MN as well as a narrower antigen reactivity spectrum of the anti-GBM antibodies present. 7 In contrast to MN without crescents, in which case >90% of patients have normal renal function at presentation 1 and hematuria is generally microscopic and low-grade, S2 most of our patients had significant hematuria, and approximately 75% presented with severe kidney dysfunction. In addition, although approximately 80% of cases of MN without crescents are considered primary, in our series only 26% of cases were PLA2R positive, and 40% were IgG4 dominant/co-dominant. Therefore, it appears that crescents occur more often in cases of secondary MN.
In conclusion, MN with crescents is a rare and heterogeneous entity that can be associated with ANCA, anti-GBM, PLA2R, and potentially other autoantibodies. It presents more often with significant hematuria and renal dysfunction than MN without crescents and progresses more often to ESRD. Whether these cases represent a coincidental occurrence of 2 separate disease entities or whether they are pathogenically related remains to be determined, 8 although the latter is conceivable. For example, subepithelial deposits may facilitate GBM damage, leading to anti-GBM antibody production. Conversely, GBM damage caused by anti-GBM (or other) antibodies could expose epitopes that lead to immune-complex deposition along the subepithelial aspect of the GBM.
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